PMID- 27367264 OWN - NLM STAT- MEDLINE DCOM- 20170912 LR - 20181202 IS - 1473-5598 (Electronic) IS - 0263-6352 (Linking) VI - 34 IP - 9 DP - 2016 Sep TI - Depressed myocardial energetic efficiency is associated with increased cardiovascular risk in hypertensive left ventricular hypertrophy. PG - 1846-53 LID - 10.1097/HJH.0000000000001007 [doi] AB - BACKGROUND AND PURPOSE: Myocardial mechano-energetic efficiency (MEE) can be easily approximated by the ratio of stroke work [i.e. SBP times stroke volume (SV)] to a rough estimate of energy consumption, the 'double product' [SBP times heart rate (HR)], which can be simplified as SV/HR. We evaluated whether MEE is associated with adverse prognosis in relation to the presence of left ventricular hypertrophy (LVH). METHODS: Hypertensive participants of the Campania Salute Network (n = 12 353) without prevalent coronary or cerebrovascular disease and with ejection fraction more than 50% were cross-sectionally and longitudinally analyzed, over a median follow-up of 31 months. MEE was estimated by echocardiographic SV (z-derived)/(HR x 0.6). RESULTS: Due to the close relation with left ventricular mass (LVM) (P < 0.0001), MEE was normalized for LVM (MEEi) and divided into quartiles. The lowest quartile of MEEi (<0.29 ml/s per g) was considered 'low MEEi'. MEEi was greater in women than in men (P < 0.0001). Progressively lower MEEi was associated with older age, male sex, obesity, diabetes, LVH, concentric geometry, inappropriate LVM and diastolic dysfunction, more use of antihypertensive therapy, and higher BP (all P < 0.002). In Cox regression, after controlling for LVH, age, sex, and average follow-up SBP, low MEEi exhibited increased hazard of composite fatal and nonfatal cardiovascular end-points (P < 0.01), independently of antihypertensive therapy and associated cardiovascular risk factors. CONCLUSION: A simple estimate of low myocardial mechano-energetic efficiency is associated with altered metabolic profile, LVH, concentric left ventricular geometry, and diastolic dysfunction and predicts cardiovascular end-points, independently of age, sex, LVH antihypertensive therapy, and cardiovascular risk factors. FAU - de Simone, Giovanni AU - de Simone G AD - aHypertension Research Center bDepartment of Advanced Translational Medical Sciences cDepartment of Biomedical Sciences dDepartment of Neurosciences, Federico II University Hospital, Napoli, Italy. FAU - Izzo, Raffaele AU - Izzo R FAU - Losi, Maria Angela AU - Losi MA FAU - Stabile, Eugenio AU - Stabile E FAU - Rozza, Francesco AU - Rozza F FAU - Canciello, Grazia AU - Canciello G FAU - Mancusi, Costantino AU - Mancusi C FAU - Trimarco, Valentina AU - Trimarco V FAU - De Luca, Nicola AU - De Luca N FAU - Trimarco, Bruno AU - Trimarco B LA - eng PT - Journal Article PL - Netherlands TA - J Hypertens JT - Journal of hypertension JID - 8306882 SB - IM MH - Adult MH - Aged MH - *Blood Pressure MH - Cardiovascular Diseases/epidemiology MH - Cross-Sectional Studies MH - Echocardiography MH - Energy Metabolism MH - Female MH - Heart/*physiopathology MH - Humans MH - Hypertension/complications/*physiopathology MH - Hypertrophy, Left Ventricular/complications/*physiopathology MH - Italy/epidemiology MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Myocardium MH - Prognosis MH - Risk Factors MH - *Stroke Volume EDAT- 2016/07/02 06:00 MHDA- 2017/09/13 06:00 CRDT- 2016/07/02 06:00 PHST- 2016/07/02 06:00 [entrez] PHST- 2016/07/02 06:00 [pubmed] PHST- 2017/09/13 06:00 [medline] AID - 10.1097/HJH.0000000000001007 [doi] PST - ppublish SO - J Hypertens. 2016 Sep;34(9):1846-53. doi: 10.1097/HJH.0000000000001007.